Coriolis Pharma Excels With TOP10 Listed Articles in JPharmSci
Published: Jun 05, 2012
“Such a triple is the first time ever in the Journal’s history and we feel very pleased about this appreciation of our scientific activities. Moreover, the high interest from researchers all over the world in downloading our papers give us the confidence to continue operating at the cutting edge in this field and sharing our knowledge with the scientific community and our customers”, states Dr. Michael Wiggenhorn, CEO of Coriolis Pharma.
JPharmSci allows free download of the TOP10 papers until end of June including three papers with involvement from Coriolis Pharma:
Forced degradation of therapeutic proteins
Andrea Hawe , Michael Wiggenhorn, Marco van de Weert, Joerg H. O. Garbe, Hanns-Christian Mahler, Wim Jiskoot Particles in therapeutic protein formulations, Part 1: Overview of analytical methods
Sarah Zölls, Ruedeeporn Tantipolphan, Michael Wiggenhorn, Gerhard Winter, Wim Jiskoot, Wolfgang Friess, Andrea Hawe
Protein instability and immunogenicity: Roadblocks to clinical application of injectable protein delivery systems for sustained release
Wim Jiskoot, Theodore W. Randolph, David B. Volkin, C. Russell Middaugh, Christian Schöneich, Gerhard Winter, Wolfgang Friess, Daan J. A. Crommelin, John F. Carpenter
More highly relevant publications from Coriolis Pharma related to protein aggregation analysis, particle characterization and formulation development for biopharmaceuticals can be found on http://www.coriolis-pharma.com/publications.html.
About Coriolis Pharma
Coriolis Pharma is a globally operating independent service provider for research and development of (bio)pharmaceutical drugs (proteins, peptides, monoclonal antibodies, RNA/DNA etc.) and vaccines.
An interdisciplinary team of highly qualified scientists with many years of experience in the development of (bio)pharmaceuticals supported by an expert scientific advisory board provides cutting-edge service and know-how related to the formulation development of biopharmaceuticals.
This may involve for example formulation development of (pre-)clinical material through to commercial products, lyophilization processes, stability testing (light obscuration, Micro-Flow Imaging and AF4/HF5 under cGMP), supply of pre-clinical material, and innovative analytical technologies for aggregate analysis and particle characterization.
Dr. Michael Wiggenhorn, CEO
Am Klopferspitz 19
Phone: +49 (0) 89 – 5 42 44 98-0